PMC:7253235 / 39796-43444 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T7","span":{"begin":2145,"end":2148},"obj":"https://glytoucan.org/Structures/Glycans/G00063MO"},{"id":"T8","span":{"begin":3550,"end":3553},"obj":"https://glytoucan.org/Structures/Glycans/G00063MO"}],"text":"Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic\nCardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure\nInitiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19\n• Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)\n• Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”\n• Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers\n• Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting\n• Preoperative/procedural screening and testing for COVID-19\n• Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic\n• Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy\n• Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible\n• Consideration of minimizing surveillance/staging imaging during and after treatments\nCardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias\nCardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms\nBMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction"}

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T116","span":{"begin":370,"end":384},"obj":"Body_part"},{"id":"T117","span":{"begin":1236,"end":1249},"obj":"Body_part"},{"id":"T118","span":{"begin":3164,"end":3168},"obj":"Body_part"},{"id":"T119","span":{"begin":3172,"end":3176},"obj":"Body_part"},{"id":"T120","span":{"begin":3214,"end":3219},"obj":"Body_part"},{"id":"T121","span":{"begin":3229,"end":3234},"obj":"Body_part"},{"id":"T122","span":{"begin":3393,"end":3404},"obj":"Body_part"},{"id":"T123","span":{"begin":3554,"end":3569},"obj":"Body_part"},{"id":"T124","span":{"begin":3594,"end":3599},"obj":"Body_part"}],"attributes":[{"id":"A116","pred":"fma_id","subj":"T116","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A117","pred":"fma_id","subj":"T117","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A118","pred":"fma_id","subj":"T118","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A119","pred":"fma_id","subj":"T119","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A120","pred":"fma_id","subj":"T120","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A121","pred":"fma_id","subj":"T121","obj":"http://purl.org/sig/ont/fma/fma67264"},{"id":"A122","pred":"fma_id","subj":"T122","obj":"http://purl.org/sig/ont/fma/fma9608"},{"id":"A123","pred":"fma_id","subj":"T123","obj":"http://purl.org/sig/ont/fma/fma49893"},{"id":"A124","pred":"fma_id","subj":"T124","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic\nCardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure\nInitiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19\n• Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)\n• Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”\n• Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers\n• Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting\n• Preoperative/procedural screening and testing for COVID-19\n• Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic\n• Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy\n• Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible\n• Consideration of minimizing surveillance/staging imaging during and after treatments\nCardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias\nCardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms\nBMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T53","span":{"begin":370,"end":384},"obj":"Body_part"},{"id":"T54","span":{"begin":1236,"end":1249},"obj":"Body_part"},{"id":"T55","span":{"begin":3164,"end":3168},"obj":"Body_part"},{"id":"T56","span":{"begin":3172,"end":3176},"obj":"Body_part"},{"id":"T57","span":{"begin":3214,"end":3219},"obj":"Body_part"},{"id":"T58","span":{"begin":3393,"end":3404},"obj":"Body_part"},{"id":"T59","span":{"begin":3554,"end":3569},"obj":"Body_part"},{"id":"T60","span":{"begin":3563,"end":3569},"obj":"Body_part"},{"id":"T61","span":{"begin":3594,"end":3599},"obj":"Body_part"}],"attributes":[{"id":"A53","pred":"uberon_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"A54","pred":"uberon_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"A55","pred":"uberon_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A56","pred":"uberon_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A57","pred":"uberon_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A58","pred":"uberon_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/UBERON_0002371"},{"id":"A59","pred":"uberon_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/UBERON_0001621"},{"id":"A60","pred":"uberon_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"A61","pred":"uberon_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic\nCardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure\nInitiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19\n• Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)\n• Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”\n• Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers\n• Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting\n• Preoperative/procedural screening and testing for COVID-19\n• Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic\n• Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy\n• Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible\n• Consideration of minimizing surveillance/staging imaging during and after treatments\nCardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias\nCardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms\nBMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction"}

LitCovid-PD-MONDO

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T115","span":{"begin":560,"end":568},"obj":"Chemical"},{"id":"T116","span":{"begin":1837,"end":1845},"obj":"Chemical"},{"id":"T117","span":{"begin":2427,"end":2430},"obj":"Chemical"},{"id":"T118","span":{"begin":2643,"end":2657},"obj":"Chemical"},{"id":"T120","span":{"begin":3229,"end":3234},"obj":"Chemical"},{"id":"T121","span":{"begin":3437,"end":3444},"obj":"Chemical"}],"attributes":[{"id":"A115","pred":"chebi_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/CHEBI_78059"},{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_78059"},{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_28398"},{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_48120"},{"id":"A119","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_49322"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic\nCardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure\nInitiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19\n• Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)\n• Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”\n• Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers\n• Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting\n• Preoperative/procedural screening and testing for COVID-19\n• Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic\n• Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy\n• Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible\n• Consideration of minimizing surveillance/staging imaging during and after treatments\nCardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias\nCardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms\nBMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction"}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T28","span":{"begin":2241,"end":2247},"obj":"http://purl.obolibrary.org/obo/GO_0048511"}],"text":"Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic\nCardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure\nInitiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19\n• Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)\n• Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”\n• Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers\n• Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting\n• Preoperative/procedural screening and testing for COVID-19\n• Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic\n• Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy\n• Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible\n• Consideration of minimizing surveillance/staging imaging during and after treatments\nCardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias\nCardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms\nBMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction"}

LitCovid-PD-HP

LitCovid-sentences

PMC:7253235 / 39796-43444 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7253235 / 39796-43444 JSON TXT